Dopamine: Nursing Drug Guide, Infusion Safety & NCLEX Review

U.S. labeling describes Dopamine Hydrochloride in Dextrose Injection (premixed in 5% dextrose)—supplied as clear to slightly yellow solutions at 1,600 mcg/mL and 3,200 mcg/mL in single-dose flexible containers. Concentrate vials and other manufacturers may also appear on formularies; always match the product concentration to pump programming.

Do not confuse dopamine bags with dobutamine, norepinephrine, or epinephrine drips in the medication room.

Per FDA prescribing information, dopamine hydrochloride in dextrose injection is indicated to improve hemodynamic status in patients in distributive shock or shock due to reduced cardiac output—common ICU and emergency contexts such as sepsis with persistent hypotension after fluids, or low-output states associated with heart failure.

↔On a small screen, swipe or scroll sideways to see the full table.

Dopamine is an endogenous catecholamine and precursor to norepinephrine. At the bedside, nurses track mcg/kg/min because effects shift with rate: below about 5 mcg/kg/min, dopamine activates dopaminergic receptors (renal/mesenteric vasodilation); at 5–10 mcg/kg/min, beta-1 effects increase contractility and heart rate; above about 10 mcg/kg/min, alpha-1 vasoconstriction can raise blood pressure but also reduce peripheral perfusion if volume is inadequate.

About 75% of dopamine is metabolized by MAO and COMT; roughly 25% is converted to norepinephrine—explaining why MAO inhibitors and other vasopressors dramatically potentiate response.

Individualize to hemodynamic targets. Use an infusion pump in an intensive care setting when possible. Labeling provides this infusion-rate formula: [Dose (mcg/kg/min) × Weight (kg) × 60] ÷ Concentration (mcg/mL) = mL/hour.

MAO inhibitor patients

If the patient received an MAO inhibitor within the prior 2–3 weeks, labeling directs reducing the starting dose to no greater than one-tenth (1/10) of the usual starting dose because of severe hypertension and arrhythmia risk.

Renal / hepatic impairment: Not specified in the reviewed prescribing information for dose adjustment beyond standard titration.

Missed dose: Not applicable to continuous infusion—if interrupted, verify line patency, compatibility, and prescriber direction before restarting; taper when discontinuing.

Pretreatment checks

• Confirm hypovolemia, acidosis, and hypoxia are being treated—fluids and source control before vasopressors when shock is hypovolemic
• Perform medication reconciliation for MAO inhibitors, tricyclic antidepressants, halogenated anesthetics, and concurrent vasopressors
• Obtain weight in kilograms; program pump in mcg/kg/min with independent double-check
• Establish large-vein access through a central catheter when ordered; follow facility central-line care standards and assess the site every hour
• Attach cardiac monitoring; document baseline blood pressure, heart rate, rhythm, and urine output
• Screen for sulfite sensitivity (product contains sodium metabisulfite) and history of asthma

Contraindications

• Pheochromocytoma (labeled contraindication)

Warnings (labeling)

• Tissue ischemia: Hypovolemic patients may develop severe vasoconstriction, poor renal perfusion, and lactic acidosis despite normal BP readings
• Extravasation: Necrosis—infuse into large vein; treat with phentolamine infiltration per label
• Arrhythmias: Monitor and treat; risk increased with halogenated anesthetics or MAO inhibitors
• Abrupt stop: Marked hypotension—taper rate while expanding intravascular volume
• Sulfite excipient: May cause anaphylaxis or bronchospasm in susceptible patients

Important interactions

↔On a small screen, swipe or scroll sideways to see the full table.

Incompatibilities (same infusion set): Sodium bicarbonate or alkalinizing agents, blood products, iron salts. Do not add medications to the premixed bag.

Route: Intravenous continuous infusion only. Premixed dopamine in 5% dextrose does not require dilution. Administer through a large vein with an infusion pump, preferably in intensive care. Inspect solution—clear to slightly yellow; do not use if darker than slightly yellow or container is damaged. Discard unused portion (single-dose container).

• Remove outer oxygen/moisture wrap only when ready to hang; verify concentration (1,600 vs 3,200 mcg/mL) matches the order
• Use IV infusion pump setup with mcg/kg/min or verified mL/hour after weight-based calculation
• Check infusion site frequently for free flow, swelling, coolness, blanching, or pain
• Keep phentolamine and protocol supplies available for extravasation

• Improved mean arterial pressure and perfusion after appropriate volume resuscitation
• Urine output and mental status improve when renal and cerebral perfusion recover
• Heart rate and rhythm remain acceptable on monitor—excessive tachycardia may signal dose too high
• Lactate and clinical perfusion trend improve when shock is resolving—reassess if lactate rises despite “normal” BP

Escalate immediately for extravasation, ischemia, or life-threatening rhythm changes.

• Extravasation, blanching, coolness, or severe pain at the IV site—stop infusion and initiate phentolamine infiltration per labeling
• New sustained ventricular palpitations or wide-complex tachycardia on monitor
• Gangrene, mottling, or absent distal pulses—especially with occlusive vascular disease or high-dose prolonged infusion
• Oliguria and rising lactate despite acceptable blood pressure—suspect occult hypovolemia or visceral ischemia
• Severe headache, chest pain, or neurologic change with hypertension—possible excessive vasopressor effect

Labeling states the most common adverse reaction is localized vasoconstriction due to extravasation. Other reactions below are from warnings or postmarketing reports in the prescribing information.

↔On a small screen, swipe or scroll sideways to see the full table.

For accidental overdose, labeling directs reducing or temporarily stopping the infusion until adverse effects resolve. Because dopamine has a short duration of action, additional measures are usually unnecessary unless severe hypertension or arrhythmia persists.

Management (labeling)

• Reduce infusion rate or pause infusion
• If hypertension or arrhythmia continues, consider an alpha-adrenergic blocking agent (e.g., phentolamine) per prescriber and toxicology guidance
• Support perfusion and monitor rhythm until stable

Extravasation antidote: Phentolamine mesylate infiltration—adults: 5–10 mg in 10–15 mL 0.9% sodium chloride; pediatrics: 0.1–0.2 mg/kg up to 10 mg maximum per dose. Best within 12 hours per labeling.

Systemic antidote: No specific reversal agent listed for IV overdose.

• Dopamine vs dobutamine vs norepinephrine—triple-check MAR, bag label, and pump library selection; all are ICU drips but with different mcg/kg/min ranges and risks
• mcg/kg/min vs mg/hour vs mL/hour—independent double-check every new bag and rate change; use labeling formula with concentration in mcg/mL
• 1,600 vs 3,200 mcg/mL premixed bags—wrong concentration doubles or halves delivery at the same mL/hour
• Adding drugs to premixed bag—prohibited; incompatibilities include bicarbonate, blood, and iron salts
• Peripheral vs central access—extravasation risk is highest peripherally; label line and handoff access type

↔On a small screen, swipe or scroll sideways to see the full table.

↔On a small screen, swipe or scroll sideways to see the full table.

Monitor

• Continuous cardiac rhythm and frequent blood pressure (arterial line when available)
• Hourly urine output and perfusion (capillary refill, mental status, skin temperature)
• IV site integrity and extremity color, temperature, and pulses
• Serial lactate, BMP, and renal function when shock persists or urine output falls—see acute kidney injury cues
• Respiratory status and oxygenation

Document

• Weight (kg), concentration (mcg/mL), rate in mcg/kg/min and mL/hour, and double-check initials
• Fluid resuscitation volume and response before and during vasopressor therapy
• Each titration with time, rate, BP, HR, rhythm, and urine output response
• Extravasation events, phentolamine dose given, and prescriber notifications

• Explain that dopamine supports blood pressure and organ perfusion during shock when ordered by the critical-care team—it is not the same as home oral medicines
• Report sudden dizziness, chest pressure, shortness of breath, or palpitations immediately
• Keep the affected arm or IV site still and notify staff for pain, burning, swelling, or coolness at the catheter
• Understand that vital signs and urine output will be checked often; this monitoring prevents complications
• Family teaching: vasopressor therapy means the patient is critically ill—questions about goals of care go to the treating team

Do not give and contact the prescriber/pharmacist when:

Reduce rate (do not always fully stop) for excessive hypertension, tachycardia, or arrhythmia per prescriber and labeling—then reassess perfusion. Hold parameters may vary by institutional protocol.

Practice NCLEX-style clinical judgment practice for dopamine using a tabbed ICU case (MAR, labs, vitals, nursing notes), then priority action, cue recognition, perfusion trend interpretation, matrix urgency sorting, extravasation judgment, and phentolamine cloze—recognise cues → analyse → prioritise → act → evaluate outcomes.

This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.

• Editorial Policy
• Medical Review Process
• Disclaimer

Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.